文献速递鼻科

环丙沙星-阿奇霉素鼻窦支架体外抗铜绿假单胞菌生物膜评价

In-vitro evaluation of a ciprofloxacin and azithromycin sinus stent for Pseudomonas aeruginosa biofilms.
PubMed 文献 · Int Forum Allergy Rhinol · 2019-11-06

本研究在体外评估新型环丙沙星-阿奇霉素鼻窦支架(CASS)对铜绿假单胞菌生物膜的抑制作用。CASS以聚左旋乳酸(PLLA)为基材,内层涂环丙沙星、外层涂阿奇霉素,药物涂层均匀且可持续释放28天,并显著减少生物膜量。

要点

  • CASS能持续释放环丙沙星和阿奇霉素达28天。
  • CASS显著减少铜绿假单胞菌生物膜量。
  • 药物涂层均匀,具备靶向释放潜力。

核心结论

  • CASS能均匀涂层并持续释放环丙沙星和阿奇霉素,对铜绿假单胞菌具有抗生物膜活性。

研究设计与样本

  • 体外研究:将环丙沙星(亲水性内层)和阿奇霉素(疏水性外层)涂覆于可降解PLLA支架,评估涂层稳定性、释放动力学及抗生物膜活性。

主要发现

  • 环丙沙星(60 µg)和阿奇霉素(3 mg)均匀涂覆于PLLA支架表面。
  • 28天时环丙沙星释放80.55 ± 11.61%,阿奇霉素释放93.85 ± 6.9%。
  • CASS组生物膜量(A590)为0.037 ± 0.006,显著低于裸支架(0.911 ± 0.015)和对照组(1.000 ± 0.000),p < 0.001,n = 3。

临床怎么用

  • 提示CASS可能通过局部持续释放抗生素减少鼻窦铜绿假单胞菌生物膜,但尚需临床前模型验证。

局限性

  • 仅为体外研究,样本量小(n = 3),尚未在动物或人体中验证疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic rhinosinusitis (CRS) is a chronic inflammatory disease characterized by persistent inflammation and bacterial infection. Ciprofloxacin and azithromycin are commonly prescribed antibiotics for CRS, but the ability to provide targeted release in the sinuses could mitigate side effects and improve drug concentrations at the infected site. This study was aimed to evaluate the efficacy of the novel ciprofloxacin-azithromycin sinus stent (CASS) in vitro. METHODS: The CASS was created by coating ciprofloxacin (hydrophilic, inner layer) and azithromycin (hydrophobic, outer layer) onto a biodegradable poly-l-lactic acid (PLLA) stent. In-vitro evaluation included: (1) assessment of drug-coating stability within the stent using scanning electron microscopy (SEM); (2) determination of ciprofloxacin and azithromycin release kinetics; and (3) assessment of anti-biofilm activities against Pseudomonas aeruginosa. RESULTS: The ciprofloxacin nanoparticle suspension in the inner layer was confirmed by zeta potential. Both ciprofloxacin (60 µg) and azithromycin (3 mg) were uniformly coated on the surface of the PLLA stents. The CASS showed ciprofloxacin/azithromycin sustained release patterns, with 80.55 ± 11.61% of ciprofloxacin and 93.85 ± 6.9% of azithromycin released by 28 days. The CASS also significantly reduced P aeruginosa biofilm mass compared with bare stents and controls (relative optical density units at 590-nm optical density: CASS, 0.037 ± 0.006; bare stent, 0.911 ± 0.015; control, 1.000 ± 0.000; p < 0.001; n = 3). CONCLUSION: The CASS maintains a uniform coating and sustained delivery of ciprofloxacin and azithromycin, providing anti-biofilm activities against P aeruginosa. Further studies evaluating the efficacy of CASS in a preclinical model are planned.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Lim DJ, Skinner D, Mclemore J, et al. In-vitro evaluation of a ciprofloxacin and azithromycin sinus stent for Pseudomonas aeruginosa biofilms. Int Forum Allergy Rhinol. 2019. PMID: 31692289. doi:10.1002/alr.22475

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。